Intended for licensed healthcare professionals located in Switzerland.
Because Tomorrows Matters Today

For adult patients with CML failing on one 2G TKI, ICLUSIG® combines experience and data to improve their futures1–3*

Ph+ CML
ICLUSIG is indicated in adult patients suffering from T315I-positive Philadephia-positive (Ph+) chronic myeloid leukemia (chronic phase, accelerated phase, or blast phase), or Ph+ chronic myeloid leukemia (chronic phase, accelerated phase or blast phase) for whom a treatment with other c-abl tyrosine kinase inhibitors is not appropriate.1
Blue square
Also available
for your
patients with
Ph+ ALL
Ph+ ALL
ICLUSIG is indicated in adult patients suffering from T315I-positive Ph+ acute lymphoblastic leukemia, or Ph+ acute lymphoblastic leukemia for whom a treatment with other c-abl tyrosine kinase inhibitors is not appropriate.1